Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions

Stephanie J W Shoop-Worrall; Qiong Wu; Rebecca Davies; Kimme L Hyrich; Lucy R Wedderburn

doi:10.1016/S2352-4642(19)30188-9

Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions

Lancet Child Adolesc Health. 2019 Oct;3(10):725-733. doi: 10.1016/S2352-4642(19)30188-9. Epub 2019 Jul 19.

Authors

Stephanie J W Shoop-Worrall¹, Qiong Wu², Rebecca Davies³, Kimme L Hyrich⁴, Lucy R Wedderburn⁵

Affiliations

¹ Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK; Centre for Health Informatics, The University of Manchester, Manchester, UK.
² UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
³ Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.
⁴ Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁵ UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Centre for Adolescent Rheumatology Versus Arthritis at University College London, University College London Hospital, and Great Ormond Street Hospital, University College London, London, UK; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital, London, UK. Electronic address: [email protected].

PMID: 31331873
DOI: 10.1016/S2352-4642(19)30188-9

Abstract

The aims of treating juvenile idiopathic arthritis are to elicit treatment response toward remission, while preventing future flares. Understanding patient and disease characteristics that predispose young people with this condition to these outcomes would allow the forecasting of disease process and the tailoring of therapies. The strongest predictor of remission is disease category, particularly oligoarthritis, although a few additional clinical predictors of treatment response have been identified. Novel evidence using biomarkers, such as S100 proteins and novel single nucleotide polymorphism data, could add value to clinical models. The future aim of personalised medicine in the treatment of juvenile idiopathic arthritis will be aided with international collaborations, allowing for the analysis of larger datasets with novel biomarker data. Combined clinical and biomarker panels will probably be required for predicting outcomes in such a complex disease.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Arthritis, Juvenile* / blood
Arthritis, Juvenile* / diagnosis
Arthritis, Juvenile* / drug therapy
Biomarkers / blood
Cohort Studies
Humans
Outcome Assessment, Health Care*
Patient-Centered Care
Remission Induction / methods

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding